- $278.70bn
- $303.23bn
- $54.07bn
- 91
- 33
- 78
- 77
REG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Enhertu improved IDFS in early BC in DB-05
AnnouncementREG - AstraZeneca PLC - AZN harmonises listing structure
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementRCS - Redx Pharma Limited - Redx Pharma to present new Phase 2a data at ERS
AnnouncementREG - AstraZeneca PLC - Koselugo recommended for EU approval
AnnouncementREG - AstraZeneca PLC - Tezspire Recommended for Approval in EU for CRSwNP
AnnouncementREG - AstraZeneca PLC - Saphnelo met primary endpoint in TULIP-SC
AnnouncementREG - AstraZeneca PLC - Update on RESOLUTE Phase III trial
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Holding(s) in Company
AnnouncementREG - AstraZeneca PLC - Holding(s) in Company
AnnouncementREG - AstraZeneca PLC - Holding(s) in Company
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Holding(s) in Company
AnnouncementREG - AstraZeneca PLC - Holding(s) in Company
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - H1 and Q2 2025 results
AnnouncementREG - AstraZeneca PLC - Gefurulimab nanobody met Phase III endpoints
Announcement